Stockreport

FDA lifts clinical hold on Avidity's lead antibody conjugate therapy trial [Yahoo! Finance]

Avidity Biosciences, Inc.  (RNA) 
PDF on Avidity Biosciences' investigational drug, delpacibart etedesiran (del-desiran). In 2022, the US regulatory agency placed a partial hold after a report of a serious [Read more]